Assessments
toxicity, tumor
DISEASE, TUMOR
Interim response assessments were obtained between C4D15 and C4D21 and at primary response assessment (PRA) at the end of C8. Patients with a complete response at PRA completed treatment at C8, whereas those with a partial response or stable disease at PRA continued mosunetuzumab monotherapy for a total of 17 cycles, unless progressive disease or unacceptable toxicity occurred. The number of cycles of polatuzumab vedotin was limited to six in total, irrespective of response. Retreatment with mosunetuzumab monotherapy or mosun-pola was permitted in patients who experienced progressive disease after an initial complete response.PET and diagnostic-quality CT scans were required at screening, at the interim response assessment and at the PRA visit. During follow-up, CT scans with or without PET scans were used. Before a metabolic complete response was achieved, it was recommended that PET scans should continue in conjunction with diagnostic-quality CT scans. Additionally, if progressive disease or relapse was suspected before the PRA, both PET and diagnostic-quality CT scans should be performed for tumor assessment. Lugano 2014 criteria were used to assess overall response to study treatmentWhen determining best response, the PET scan result was used unless it was missing or not evaluable. There were five patients in whom this was the case, so the CT scan result was used instead.